Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biotechnology company Crucell has been awarded an additional contract totaling over $20 million for its Quinvaxem pediatric vaccine.
Subscribe to our email newsletter
This contract was awarded by a supranational organization for Latin America and covers sales in 2007. Supranational organizations are major customers for combination vaccines, which are used in large vaccination programs in developing countries.
The contract totals over $230 million for both its Quinvaxem and Hepavax-Gene pediatric vaccines.
Quinvaxem, a fully-liquid pentavalent vaccine for children, was co-developed with Novartis Vaccines and Diagnostics and is produced in Crucell’s laboratories in South Korea. The vaccine combines antigens for protection against five important childhood diseases: diphtheria, tetanus, whooping cough, hepatitis B and haemophilus influenzae type b.
According to Crucell, the current worldwide demand for the Quinvaxem vaccine exceeds 50 million doses per year. The total market potential is 150 million doses per year in 3 to 4 years time.